Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3305-3315

  Sacco, Assuntina G ^a   Cohen, Ezra E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALPHA2B INTERFERON; BIOLOGICAL MARKER; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMBROLIZUMAB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TEMSIROLIMUS; TOLL LIKE RECEPTOR AGONIST; UNINDEXED DRUG; VINCRISTINE; ZALUTUMUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FATALITY; GERIATRIC PATIENT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HYPOMAGNESEMIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA; REVIEW; SEPSIS; SKIN TOXICITY; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALGESIA; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; HEAD AND NECK NEOPLASMS; METASTASIS; MOLECULARLY TARGETED THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL; TUMOR RECURRENCE; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAIN MANAGEMENT; PALLIATIVE CARE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84944238588     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.0963     Document Type: Review

References (79)

1. Argiris A, Kramouzis MV, Raben D, et al: Head and neck cancer. Lancet 371: 1695-1709, 2008
2. Seiwert TY, Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92: 1341-1348, 2005
3. Marur S, Forastiere AA: Head and neck cancer: Changing epidemiology, diagnosis and treatment. Mayo Clin Proc 83: 489-501, 2008
4. Gibson MK, Li Y, Murphy B, et al: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23: 3562-3567, 2005
5. Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2644-2652, 2006
6. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008
7. Fakhry C, Zhang Q, Nguyen-Tan PF, et al: Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32: 3365-3373, 2014
8. Argiris A, Li S, Ghebremichael M, et al: Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: An analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 25: 1410-1416, 2014
9. Goodwin WJ: Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: When do the ends justify the means? Laryngoscope 110: S1-S18, 2000 (suppl 93)
10. Janot F, de Raucort D, Benhamou E, et al: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26: 5518-5523, 2008
11. De Crevoisier R, Bourhis J, Domenge C, et al: Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16: 3556-3562, 1998
12. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101: 2222-2229, 2004
13. Wittes RE, Cvitkovic E, Shah J, et al: CISDichlorodiammineplatinum( II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61: 359-366, 1977
14. Wittes R, Heller K, Randolph V, et al: Cis- Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 63: 1533-1538, 1979
15. Morton RP, Rugman F, Dorman EB, et al: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 15: 283-289, 1985
16. The Liverpool Head and Neck Oncology Group: A phase III randomised trial of cisplatinum, methotrexate, cisplatinum methotrexate and cisplatin 5-FU in end stage squamous cell carcinoma of the head and neck. Br J Cancer 61: 311-315, 1990
17. Kish JA, Weaver A, Jacobs J, et al: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53: 1819-1824, 1984
18. Clavel M, Cognetti F, Dodion P, et al: Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60: 1173-1177, 1987
19. Browman GP, Cronin L: Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 21: 311-319, 1994
20. Jacobs C, Lyman G, Velez-García E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992
21. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992
22. Clavel M, Vermorken JB, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5: 521-526, 1994
23. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck-EORTC Early Clinical Trials Group. Ann Oncol 5: 533-537, 1994
24. Dreyfuss AI, Clark JR, Norris CM, et al: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678, 1996
25. Forastiere AA, Shank D, Neuberg D, et al: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer 82: 2270-2274, 1998
26. Adamo V, Ferraro G, Pergolizzi S, et al: Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 40: 525-531, 2004
27. Gedlicka C, Formanek M, Selzer E, et al: Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncol 63: 145-150, 2002
28. Shin DM, Glisson BS, Khuri FR, et al: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 1325-1330, 1998
29. Janinis J, Papadakou M, Xidakis E, et al: Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: A phase II feasibility study. Am J Clin Oncol 23: 128-131, 2000
30. Shin DM, Khuri FR, Glisson BS, et al: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91: 1316-1323, 2001
31. Schrijvers D, Johnson J, Jiminez U, et al: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 16: 1054-1059, 1998
32. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005
33. Urba S, van Herpen CM, Sahoo TP, et al: Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: Final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer 118: 4694-4705, 2012
34. Jin Y, Shi YX, Cai XY, et al: Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138: 1717-1725, 2012
35. Degardin M, Oliveira J, Geoffrois L, et al: An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 9: 1103-1107, 1998
36. Saxman S, Mann B, Canfield V, et al: A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 21: 398-400, 1998
37. Zhang L, Zhang Y, Huang PY, et al: Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 61: 33-38, 2008
38. Rubin Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993
39. Rubin Grandis J, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998
40. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002
41. Hitt R, Irigoyen A, Cortes-Funes H, et al: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23: 1016-1022, 2012
42. Vermorken JB, Trigo J, Hitt R, et al: Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177, 2007
43. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol 14: 697-710, 2013
44. Wirth LJ, Dakhil SR, Kornek G, et al: PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 31, 2013 (suppl 15s; abstr 6029)
45. Machiels JP, Subramanian S, Ruzsa A, et al: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomized phase 3 trial. Lancet Oncol 12: 333-343, 2011
46. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1864-1871, 2009
47. Argiris A, Ghebremichael M, Gilbert J, et al: Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 31: 1405-1414, 2013
48. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85, 2004
49. de Souza JA, Davis DW, Zhang Y, et al: A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18: 2336-2343, 2012
50. Seiwert TY, Fayette J, Cupissol D, et al: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25: 1813-1820, 2014
51. Machiels J, Haddad RI, Fayette J, et al: Afatinib versus methotrexate as second-line treatment for patient with R/M HNSCC who progressed after platinum-based therapy: Primary efficacy results of LUX-Head & Neck 1, a phase III trial. Presented at the Annual Congress of the European Society for Medical Oncology, Madrid, Spain, September 26-30, 2014
52. Abdul Razak AR, Soulières D, Laurie SA, et al: A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 24: 761-769, 2013
53. Kim HS, Kwon HJ, Jung I, et al: Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res 21: 544-552, 2015
54. Rabinowits G, Haddad RI: Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature. Oral Oncol 48: 1085-1089, 2012
55. Licitra L, Mesia R, Rivera F, et al: Evaluation of EGFR copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22: 1078-1087, 2011
56. Licitra L, Störkel S, Kerr KM, et al: Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49: 1161-1168, 2013
57. Khattri A, Zuo Z, Brägelmann J, et al: Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol 51: 53-58, 2015
58. Stoehlmacher-Williams J, Obermann L, Ehninger G, et al: Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC). Anticancer Res 32: 421-425, 2012
59. Su NW, Leu YS, Lee JC, et al: EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. Onco Targets Ther 7: 2197-2204, 2014
60. Mountzios G: Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy. World J Clin Oncol 6: 7-15, 2015
61. Argiris A, Li Y, Murphy BA, et al: Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22: 262-268, 2004
62. Young ER, Diakos E, Khalid-Raja M, et al: Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: Systematic review and meta-analysis. Clin Otolaryngol 40: 208-218, 2015
63. Lui VW, Hedberg ML, Li H, et al: Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3: 761-769, 2013
64. Seiwert TY, Zuo Z, Keck MK, et al: Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21: 632-641, 2015
65. Jimeno A, Bauman JE, Weissman C, et al: A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol 51: 383-388, 2015
66. Jimeno A, Shirai K, Choi M, et al: A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol 26: 556-561, 2015
67. Gonzalez-Angulo AM, Juric D, Argiles G, et al: Safety, pharmacokinetics, and preliminary activity of the specific PI3K inhibitor BYL719: Results from the first-in-human study. J Clin Oncol 31, 2013 (suppl 18s; abstr 2531)
68. Massarelli E, Ginsberg LE, Lin H, et al: Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. J Clin Oncol 31, 2013 (suppl 15s; abstr 6067)
69. Saba NF, Hurwitz SJ, Magliocca K, et al: Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer 120: 3940-3951, 2014
70. Fury MG, Sherman E, Ho A, et al: A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol 70: 121-128, 2012
71. Bauman JE, Arias-Pulido H, Lee SJ, et al: Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 30, 2012 (suppl 15s; abstr 5549)
72. Grünwald V, Keilholz U, Boehm A, et al: TEMHEAD: A single-arm multicenter phase II study of temsirolimus in platin- and cetuximab-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol 26: 561-567, 2015
73. Kuo WL, Sharifi MN, Lingen MW, et al: P62/ SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One 9: E90171, 2014
74. Grosso J, Inzunza D, Wu Q, et al: Programmed death-ligand 1 (PD-L1) expression in various tumor types. J Immunother Cancer 1: S53, 2013 (suppl 1)
75. Lyford-Pike S, Peng S, Young GD, et al: Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73: 1733-1741, 2013
76. Badoual C, Hans S, Merillon N, et al: PD-1- expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73: 128-138, 2013
77. Chow LQ, Burtness B, Weiss J, et al: A phase Ib study of pembrolizumab (Pembo; MK-3475) in patients (Pts) with human papilloma virus (HPV)- positive and negative head and neck cancer (HNC). Ann Oncol 25: S1-S41, 2014 (suppl 4)
78. Fury M, Ou SI, Balmanoukian AS, et al: Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer. Ann Oncol 25: S340-S356, 2014 (suppl 4)
79. Chow LQM, Eaton KD, Baik C, et al: Phase Ib trial of TLR8 agonist VTX-2237 in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN). Presented at the Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ, February 20-22, 2014